Date published: 2026-5-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr375 Inhibitors

Olr375 inhibitors represent a specific class of compounds that interact with the olfactory receptor Olr375, a member of the G protein-coupled receptor (GPCR) family. These receptors are part of a vast network involved in the detection of volatile molecules, playing a crucial role in the sensory perception of smell. Olr375, like other olfactory receptors, is embedded in the membrane of olfactory sensory neurons, where it initiates a signaling cascade upon binding with specific ligands. Inhibitors targeting Olr375 function by interfering with the receptor's ability to bind its native ligands or by preventing the downstream signaling mechanisms that follow ligand-receptor interaction. The inhibition of Olr375 can be achieved through various mechanisms, such as competitive inhibition, where the inhibitor competes with the natural ligand for the active binding site, or allosteric inhibition, where the inhibitor binds to a different site on the receptor, inducing a conformational change that reduces the receptor's activity.

The study of Olr375 inhibitors is of significant interest due to their potential to modulate specific olfactory pathways, thereby providing insights into the fundamental processes of olfactory perception and signal transduction. By examining the structural features of Olr375 and its inhibitors, researchers can gain a deeper understanding of the molecular interactions that govern receptor activity. This includes the identification of key amino acid residues involved in ligand binding, the conformational dynamics of the receptor in its active and inactive states, and the impact of inhibitor binding on these structural states. Additionally, research into Olr375 inhibitors contributes to broader efforts to elucidate the structure-function relationships within the GPCR superfamily, as olfactory receptors share many common features with other GPCRs involved in various physiological processes. Understanding these relationships is crucial for advancing our knowledge of receptor biology and the molecular mechanisms underlying sensory perception.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Targets multiple kinases, potentially altering pathways in tumor growth and angiogenesis.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Src family kinase inhibitor, potentially alters signal transduction in various cancers.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$133.00
$275.00
37
(2)

HDAC inhibitor, potentially affects gene expression and protein acetylation processes.

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$75.00
$121.00
33
(1)

EGFR inhibitor, potentially disrupts signaling in non-small cell lung cancer.

Everolimus

159351-69-6sc-218452
sc-218452A
5 mg
50 mg
$131.00
$651.00
7
(1)

mTOR inhibitor, potentially impacts cell growth, proliferation, and survival pathways.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual EGFR and HER2 inhibitor, potentially affects signaling in breast cancer.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Multi-kinase inhibitor, potentially affects angiogenesis and tumor growth.

Afatinib

439081-18-2sc-364398
sc-364398A
5 mg
10 mg
$114.00
$198.00
13
(2)

Irreversible EGFR inhibitor, potentially affects cell signaling in lung cancer.

Regorafenib

755037-03-7sc-477163
sc-477163A
25 mg
50 mg
$320.00
$430.00
3
(0)

Targets multiple kinases, potentially affects growth and angiogenesis in colorectal cancer.

Osimertinib

1421373-65-0sc-507355
5 mg
$86.00
(0)

EGFR inhibitor, specifically targets T790M mutation in lung cancer.